- Home
- ACTU vs IPHA Comparison
ACTU vs IPHA Comparison
Compare ACTU & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTU
- IPHA
- Stock Information
- Founded
- ACTU 2015
- IPHA 1999
- Country
- ACTU United States
- IPHA France
- Employees
- ACTU N/A
- IPHA N/A
- Industry
- ACTU
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- ACTU
- IPHA Health Care
- Exchange
- ACTU NYSE
- IPHA Nasdaq
- Market Cap
- ACTU 135.0M
- IPHA 160.1M
- IPO Year
- ACTU 2024
- IPHA 2019
- Fundamental
- Price
- ACTU $7.26
- IPHA $2.03
- Analyst Decision
- ACTU Strong Buy
- IPHA Strong Buy
- Analyst Count
- ACTU 1
- IPHA 1
- Target Price
- ACTU $20.00
- IPHA $11.00
- AVG Volume (30 Days)
- ACTU 170.2K
- IPHA 6.5K
- Earning Date
- ACTU 09-23-2025
- IPHA 09-11-2025
- Dividend Yield
- ACTU N/A
- IPHA N/A
- EPS Growth
- ACTU N/A
- IPHA N/A
- EPS
- ACTU N/A
- IPHA N/A
- Revenue
- ACTU N/A
- IPHA $20,831,349.00
- Revenue This Year
- ACTU N/A
- IPHA $209.83
- Revenue Next Year
- ACTU N/A
- IPHA $83.15
- P/E Ratio
- ACTU N/A
- IPHA N/A
- Revenue Growth
- ACTU N/A
- IPHA N/A
- 52 Week Low
- ACTU $5.47
- IPHA $1.29
- 52 Week High
- ACTU $11.99
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- ACTU N/A
- IPHA 61.03
- Support Level
- ACTU N/A
- IPHA $1.71
- Resistance Level
- ACTU N/A
- IPHA $2.10
- Average True Range (ATR)
- ACTU 0.00
- IPHA 0.07
- MACD
- ACTU 0.00
- IPHA 0.04
- Stochastic Oscillator
- ACTU 0.00
- IPHA 82.50
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.